In October 2017, Regeneron made a deal with the Biomedical Advanced Research and Development Authority (BARDA) that the U.S. government would fund 80% of the costs for
Regeneron to develop and manufacture antibody-based medications, which subsequently, in 2020, included their COVID-19 treatments, and Regeneron would retain the right to set prices and control production.
 Experimental treatment for COVID-19 On February 4, 2020, the U.S. Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron
would pursue monoclonal antibodies to fight COVID-19.
 On March 26, 2012, Bloomberg announced that Sanofi and Regeneron were in development of a new drug that would help reduce cholesterol up to 72% more than
 His doctors obtained it from Regeneron via a compassionate use request (as clinical trials had not yet been completed and the drug had not yet been approved by the US
Food and Drug Administration (FDA)).
 In April 2022, the business announced it would acquire Checkmate Pharmaceuticals for around $250 million, enhancing its number of immuno-oncology drugs.
 • Eylea (aflibercept injection) was approved by the U.S. Food and Drug Administration (FDA) in November 2011 to treat a common cause of blindness
in the elderly.
 Regeneron similarly said in its own news release that same day that “the government has committed to making doses from these lots available to the American people at
no cost and would be responsible for their distribution,” noting that this depended on the government granting emergency use authorization or product approval.
The new drug would target the PCSK9 gene.
 In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialize new immuno-oncology drugs, which could generate more
than $2 billion for Regeneron, with $640 million upfront, $750 million for proof-of-concept data, and $650 million from the development of REGN2810.
“By funding this manufacturing effort, the federal government will own the doses expected to result from the demonstration project,” the government said in its July 7 news
 In July 2020, under Operation Warp Speed, Regeneron was awarded a $450 million government contract to manufacture and supply its experimental treatment REGN-COV2, an
artificial “antibody cocktail” which was then undergoing clinical trials for its potential both to treat people with COVID-19 and to prevent SARS-CoV-2 coronavirus infection.
It was approved by the FDA in March 2017 and is reported to cost $37,000 per year.
 Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow
Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.
Approved by the FDA in July 2015, It is reported to cost $4,500 to $8,000 per year.
In October 2020, the U.S. Food and Drug Administration (FDA) approved it with an indication for the treatment of infection caused by Zaire ebolavirus.
 Such deals are not unusual for routine drug development in the American pharmaceutical market.
[‘1. “Regeneron Pharmaceuticals, Inc. 2022 Annual Report (Form 10-K)”. U.S. Securities and Exchange Commission. February 6, 2023.
2. ^ Jump up to:a b Herper, Matthew (August 14, 2013). “How Two Guys From Queens Are Changing Drug Discovery”. Forbes.
Archived from the original on March 16, 2014. Retrieved March 22, 2014.
3. ^ Jump up to:a b c d e “Regeneron’s Billionaire Founder Battles The Drug Pricing System”. Forbes. 26 July 2018. Retrieved 26 July 2018.
4. ^ “Sanofi-Regeneron Drug Lowers
Cholesterol Up to 72% in Study”. Bloomberg. 26 March 2012. Retrieved 25 July 2021.
5. ^ Staff (July 28, 2015). “Regeneron, Sanofi Launch $2B+ Immuno-Oncology Collaboration”. Genetic Engineering & Biotechnology News. Archived from the original on
September 21, 2020. Retrieved October 9, 2022.
6. ^ Carroll, John (July 28, 2015). “UPDATED: Struggling Sanofi paying $1.8B to partner with Regeneron on immuno-oncology”. FierceBiotech. Archived from the original on May 4, 2016. Retrieved October
7. ^ Hough, Jack (December 18, 2019). “10 Stocks That Had Better Decades Than Amazon and Google”. Barron’s. Archived from the original on December 18, 2019. Retrieved December 19, 2019.
8. ^ Jump up to:a b Mazzucato, Mariana; Momenghalibaf,
Azzi (March 18, 2020). “Drug Companies Will Make a Killing From Coronavirus”. The New York Times. Archived from the original on March 18, 2020. Retrieved October 9, 2022.
9. ^ Pagliarulo, Ned (February 4, 2020). “Regeneron partners with US government
to develop coronavirus treatment”. BioPharma Dive. Washington, D.C.: Industry Dive. Archived from the original on February 27, 2020. Retrieved July 25, 2021.
10. ^ Protard, Matthieu (May 25, 2020). “U.S.’ Regeneron to buy back $5 billion stake
held by Sanofi”. Reuters. Ed. John Stonestreet. Archived from the original on October 18, 2020. Retrieved October 9, 2022.
11. ^ “Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration”. Sanofi. May
25, 2020. Retrieved February 17, 2023.
12. ^ “Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types” (Press release). Regeneron. April 19, 2022. Retrieved October 9, 2022
– via BioSpace.
13. ^ News Division (4 February 2020). “HHS, Regeneron Collaborate to Develop 2019-nCoV Treatment”. HHS.gov. Retrieved 8 October 2020.
14. ^ Kelland, Kate (2020-09-14). “Regeneron’s antibody drug added to UK Recovery trial of
COVID treatments”. Reuters. Retrieved 2020-10-08.
15. ^ Morelle, Rebecca (2020-09-14). “Antibody treatment to be given to Covid patients”. BBC News. Retrieved 2020-10-08.
16. ^ “Regeneron’s COVID-19 Response Efforts”. Regeneron Pharmaceuticals
Inc. Retrieved 2020-10-08.
17. ^ News Division (6 July 2020). “HHS, DOD Collaborate with Regeneron on Large-Scale Manufacturing Demonstration Project of COVID-19 Investigational Therapeutic Treatment”. HHS.gov. Retrieved 8 October 2020.
Regeneron (7 July 2020). “Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail”. Regeneron Pharmaceuticals Inc. Retrieved 2020-10-08.
19. ^ Largacha, María Cecilia
(6 August 2020). “2 ecuatorianos, cerca del medicamento contra el Covid-19”. YouTube. Archived from the original on 2021-12-21. Retrieved 13 October 2020.
20. ^ “Trump taking Regeneron drug, Remdesivir therapy for coronavirus diagnosis: ex-WH doctor
explains”. Associated Press. Associated Press. 2020-10-03. Retrieved 2020-10-13.
21. ^ Cunningham, Paige Winfield. “Analysis | The Health 202: Trump is taking Regeneron’s new coronavirus treatment. It’s used for mild symptoms” – via www.washingtonpost.com.
Trump, Donald (7 October 2020). “A Message From The President!”. Twitter. Retrieved 7 October 2020.
23. ^ Regeneron (7 October 2020). “Statement on REGN-COV2 Emergency Use Authorization Request (PDF)”. Regeneron Pharmaceuticals Inc. Retrieved 8
24. ^ Conover, Damien (January 19, 2021). “Biopharma Companies With COVID-19 Treatments See $10 Billion Market in 2021”. Morningstar.com. Retrieved 2021-01-19.
25. ^ “Regulators Approve a Drug for an Eye Condition”. The New York
Times. Associated Press. November 18, 2011.
26. ^ “FDA approves Zaltrap for metastatic colorectal cancer” (Press release). U.S. Food and Drug Administration (FDA). August 3, 2012. Archived from the original on June 25, 2013.
27. ^ “FDA approves
Praluent to treat certain patients with high cholesterol” (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 2015-07-27. Retrieved 2015-07-29.
28. ^ Tirrell, Meg (2018-05-01). “A $14,000 cholesterol drug gets
a price cut as Regeneron, Sanofi strike deal with Express Scripts”. CNBC. Retrieved 2018-08-22.
29. ^ “Regeneron and Sanofi Announce FDA Approval of Dupixent (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic
Dermatitis” (Press release). Regeneron Pharmaceuticals Inc. – via PRNewswire.
30. ^ “Regeneron and Sanofi Announce FDA Approval of Kevzara (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (NASDAQ:REGN)”.
Regeneron Pharmaceuticals Inc. (Press release).
31. ^ “Regeneron’s COVID-19 Response Efforts”. Regeneron Pharmaceuticals Inc.
32. ^ “Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19”. clinicaltrials.gov.
30 September 2020.
33. ^ “FDA approves first treatment for advanced form of the second most common skin cancer”. U.S. Food and Drug Administration (FDA) (Press release). 2019-09-11.
34. ^ “FDA Approves First Treatment for Ebola Virus”. U.S. Food
and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020. This article incorporates text from this source, which is in the public domain.
35. ^ Susana Magadán Mompó and África González-Fernández. “Human Monoclonal
Antibodies from Transgenic Mice”. Chapter 13 in Human Monoclonal Antibodies: Methods and Protocols Ed. Michael Steinitz. Springer Science+Business Media, 2014. ISBN 978-1627035859
36. ^ “Regeneron Pharmaceuticals Revenue 2006–2021 | REGN”. Stock
Research. MacroTrends. Table (Regeneron Pharmaceuticals Annual Revenue). Retrieved July 26, 2021.
Photo credit: https://www.flickr.com/photos/clairity/3179751458/’]